Filana Therapeutics, Inc. Research and Development Expense
Filana Therapeutics, Inc. (FLNA) reported Research and Development Expense of $4.54 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-07
- Filana Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $4.54M, a 66.75% decline year-over-year.
- Filana Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $3.85M, a 81.23% decline year-over-year.
- Filana Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $3.96M, a 77.63% decline year-over-year.
- Filana Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $5.12M, a 66.34% decline year-over-year.
- Filana Therapeutics, Inc. research and development expense for fiscal 2025 was $26.59M, a 61.82% decline from fiscal 2024.
- Filana Therapeutics, Inc. research and development expense for fiscal 2024 was $69.64M, a 22.13% decline from fiscal 2023.
- Filana Therapeutics, Inc. research and development expense for fiscal 2023 was $89.42M, a 31.44% increase from fiscal 2022.
- Filana Therapeutics, Inc. research and development expense for fiscal 2022 was $68.03M, a 174.18% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $4.54M 10-Q · filed 2026-05-07 | $8.40M derived: sum of 2 quarters · filed 2026-05-07 | $12.35M derived: sum of 3 quarters · filed 2026-05-07 | $17.47M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $7.81M derived: sum of 2 quarters · filed 2026-03-12 | $12.92M derived: sum of 3 quarters · filed 2026-03-12 | $26.59M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $3.96M 10-Q · filed 2025-11-12 | $9.07M derived: sum of 2 quarters · filed 2025-11-12 | $22.74M 10-Q · filed 2025-11-12 | $43.27M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-06-30 | $5.12M 10-Q · filed 2025-08-14 | $18.78M 10-Q · filed 2025-08-14 | $39.31M derived: sum of 3 quarters · filed 2026-05-07 | $56.99M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-03-31 | $13.67M 10-Q · filed 2026-05-07 | $34.20M derived: sum of 2 quarters · filed 2026-05-07 | $51.87M derived: sum of 3 quarters · filed 2026-05-07 | $67.07M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $20.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $38.21M derived: sum of 2 quarters · filed 2026-03-12 | $53.40M derived: sum of 3 quarters · filed 2026-03-12 | $69.64M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $17.68M 10-Q · filed 2025-11-12 | $32.87M derived: sum of 2 quarters · filed 2025-11-12 | $49.11M 10-Q · filed 2025-11-12 | $67.84M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $15.20M 10-Q · filed 2025-08-14 | $31.43M 10-Q · filed 2025-08-14 | $50.16M derived: sum of 3 quarters · filed 2026-03-12 | $73.77M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $16.23M 10-Q · filed 2025-05-08 | $34.96M derived: sum of 2 quarters · filed 2026-03-12 | $58.57M derived: sum of 3 quarters · filed 2026-03-12 | $83.54M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $42.33M derived: sum of 2 quarters · filed 2026-03-12 | $67.30M derived: sum of 3 quarters · filed 2026-03-12 | $89.42M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $23.60M 10-Q · filed 2024-11-07 | $48.57M derived: sum of 2 quarters · filed 2024-11-07 | $70.69M 10-Q · filed 2024-11-07 | $88.34M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $24.97M 10-Q · filed 2024-08-08 | $47.09M 10-Q · filed 2024-08-08 | $64.74M derived: sum of 3 quarters · filed 2025-03-03 | $83.27M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $22.12M 10-Q · filed 2024-05-10 | $39.77M derived: sum of 2 quarters · filed 2025-03-03 | $58.30M derived: sum of 3 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $17.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $36.18M derived: sum of 2 quarters · filed 2025-03-03 | $68.03M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $18.53M 10-Q · filed 2023-11-07 | $50.38M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $24.81M 10-K · filed 2024-02-28 | ||||
| 2019-06-30 | $308.00K 10-Q · filed 2019-08-12 | $882.00K 10-Q · filed 2019-08-12 | $884.00K derived: sum of 3 quarters · filed 2019-08-12 | $2.35M derived: sum of 4 quarters · filed 2019-08-12 | |
| 2019-03-31 | $574.00K 10-Q · filed 2019-05-02 | $576.00K derived: sum of 2 quarters · filed 2019-05-02 | $2.04M derived: sum of 3 quarters · filed 2019-08-12 | $3.50M derived: sum of 4 quarters · filed 2019-08-12 | |
| 2018-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $1.47M derived: sum of 2 quarters · filed 2019-08-12 | $2.93M derived: sum of 3 quarters · filed 2019-08-12 | $2.97M 10-K · filed 2019-03-29 | |
| 2018-09-30 | $1.46M 10-Q · filed 2019-08-12 | $436.00K 10-Q · filed 2018-10-30 | $2.93M derived: sum of 2 quarters · filed 2019-08-12 | $2.97M 10-Q · filed 2018-10-30 | $5.54M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-06-30 | $1.46M 10-Q · filed 2018-07-26 | $2.53M 10-Q · filed 2019-08-12 | $4.08M derived: sum of 3 quarters · filed 2019-05-02 | $5.69M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2018-03-31 | $1.07M 10-Q · filed 2019-05-02 | $2.61M derived: sum of 2 quarters · filed 2019-05-02 | $4.23M derived: sum of 3 quarters · filed 2019-05-02 | $7.29M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2017-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $3.16M derived: sum of 2 quarters · filed 2019-03-29 | $6.23M derived: sum of 3 quarters · filed 2019-03-29 | $7.62M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $1.62M 10-Q · filed 2018-10-30 | $4.68M derived: sum of 2 quarters · filed 2018-10-30 | $6.07M 10-Q · filed 2018-10-30 | $7.41M derived: sum of 4 quarters · filed 2018-10-30 | |
| 2017-06-30 | $3.06M 10-Q · filed 2018-07-26 | $4.45M 10-Q · filed 2018-07-26 | $5.79M derived: sum of 3 quarters · filed 2018-07-26 | $8.44M derived: sum of 4 quarters · filed 2018-07-26 | |
| 2017-03-31 | $1.39M 10-Q · filed 2018-05-09 | $2.72M derived: sum of 2 quarters · filed 2018-05-09 | $5.38M derived: sum of 3 quarters · filed 2018-05-09 | $6.97M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-06 | $3.99M derived: sum of 2 quarters · filed 2018-02-06 | $5.58M derived: sum of 3 quarters · filed 2018-02-06 | $9.18M 10-K · filed 2018-02-06 | |
| 2016-09-30 | $2.66M 10-Q · filed 2017-11-01 | $4.25M derived: sum of 2 quarters · filed 2017-11-01 | $7.84M 10-Q · filed 2017-11-01 | $11.46M derived: sum of 4 quarters · filed 2017-11-01 | |
| 2016-06-30 | $1.59M 10-Q · filed 2017-08-09 | $5.18M 10-Q · filed 2017-08-09 | $8.80M derived: sum of 3 quarters · filed 2017-08-09 | $11.16M derived: sum of 4 quarters · filed 2017-08-09 | |
| 2016-03-31 | $3.60M 10-Q · filed 2017-04-26 | $7.21M derived: sum of 2 quarters · filed 2017-04-26 | $9.57M derived: sum of 3 quarters · filed 2017-04-26 | $11.56M derived: sum of 4 quarters · filed 2017-04-26 | |
| 2015-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $5.98M derived: sum of 2 quarters · filed 2017-03-07 | $7.96M derived: sum of 3 quarters · filed 2017-03-07 | $9.10M 10-K · filed 2017-03-07 | |
| 2015-09-30 | $2.36M 10-Q · filed 2016-10-26 | $4.34M derived: sum of 2 quarters · filed 2016-10-26 | $5.48M 10-Q · filed 2016-10-26 | $6.59M derived: sum of 4 quarters · filed 2017-03-07 | |
| 2015-06-30 | $1.99M 10-Q · filed 2016-07-19 | $3.12M 10-Q · filed 2016-07-19 | $4.23M derived: sum of 3 quarters · filed 2017-03-07 | $6.35M derived: sum of 4 quarters · filed 2017-03-07 | |
| 2015-03-31 | $1.14M 10-Q · filed 2016-05-05 | $2.25M derived: sum of 2 quarters · filed 2017-03-07 | $4.36M derived: sum of 3 quarters · filed 2017-03-07 | $6.30M derived: sum of 4 quarters · filed 2017-03-07 | |
| 2014-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $3.22M derived: sum of 2 quarters · filed 2017-03-07 | $5.16M derived: sum of 3 quarters · filed 2017-03-07 | $7.31M 10-K · filed 2017-03-07 | |
| 2014-09-30 | $2.12M 10-Q · filed 2015-11-09 | $4.05M derived: sum of 2 quarters · filed 2015-11-09 | $6.20M 10-Q · filed 2015-11-09 | $7.35M derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-06-30 | $1.94M 10-Q · filed 2015-07-23 | $4.08M 10-Q · filed 2015-07-23 | $5.23M derived: sum of 3 quarters · filed 2016-03-03 | $6.68M derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-03-31 | $2.15M 10-Q · filed 2015-05-08 | $3.30M derived: sum of 2 quarters · filed 2016-03-03 | $4.74M derived: sum of 3 quarters · filed 2016-03-03 | $5.88M derived: sum of 4 quarters · filed 2016-03-03 | |
| 2013-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $2.60M derived: sum of 2 quarters · filed 2016-03-03 | $3.73M derived: sum of 3 quarters · filed 2016-03-03 | $4.92M 10-K · filed 2016-03-03 | |
| 2013-09-30 | $1.44M 10-Q · filed 2014-11-05 | $2.58M derived: sum of 2 quarters · filed 2014-11-05 | $3.77M 10-Q · filed 2014-11-05 | $5.87M derived: sum of 4 quarters · filed 2015-02-18 | |
| 2013-06-30 | $1.14M 10-Q · filed 2014-08-06 | $2.32M 10-Q · filed 2014-08-06 | $4.42M derived: sum of 3 quarters · filed 2015-02-18 | $6.80M derived: sum of 4 quarters · filed 2015-02-18 | |
| 2013-03-31 | $1.18M 10-Q · filed 2014-05-07 | $3.28M derived: sum of 2 quarters · filed 2015-02-18 | $5.66M derived: sum of 3 quarters · filed 2015-02-18 | $7.18M derived: sum of 4 quarters · filed 2015-02-18 | |
| 2012-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $4.48M derived: sum of 2 quarters · filed 2015-02-18 | $6.00M derived: sum of 3 quarters · filed 2015-02-18 | $7.61M 10-K · filed 2015-02-18 | |
| 2012-09-30 | $2.38M 10-Q · filed 2013-11-01 | $3.90M derived: sum of 2 quarters · filed 2013-11-01 | $5.50M 10-Q · filed 2013-11-01 | $7.21M derived: sum of 4 quarters · filed 2014-02-05 | |
| 2012-06-30 | $1.52M 10-Q · filed 2013-08-01 | $3.13M 10-Q · filed 2013-08-01 | $4.84M derived: sum of 3 quarters · filed 2014-02-05 | $6.86M derived: sum of 4 quarters · filed 2014-02-05 | |
| 2012-03-31 | $1.61M 10-Q · filed 2013-04-24 | $3.32M derived: sum of 2 quarters · filed 2014-02-05 | $5.34M derived: sum of 3 quarters · filed 2014-02-05 | $7.73M derived: sum of 4 quarters · filed 2014-02-05 | |
| 2011-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-05 | $3.73M derived: sum of 2 quarters · filed 2014-02-05 | $6.12M derived: sum of 3 quarters · filed 2014-02-05 | $8.30M 10-K · filed 2014-02-05 | |
| 2011-09-30 | $2.02M 10-Q · filed 2012-11-09 | $4.41M derived: sum of 2 quarters · filed 2012-11-09 | $6.59M 10-Q · filed 2012-11-09 | $14.60M derived: sum of 4 quarters · filed 2013-02-08 | |
| 2011-06-30 | $2.39M 10-Q · filed 2012-08-02 | $4.57M 10-Q · filed 2012-08-02 | $12.58M derived: sum of 3 quarters · filed 2013-02-08 | $14.94M derived: sum of 4 quarters · filed 2013-02-08 | |
| 2011-03-31 | $2.18M 10-Q · filed 2012-05-08 | $10.19M derived: sum of 2 quarters · filed 2013-02-08 | $12.55M derived: sum of 3 quarters · filed 2013-02-08 | $14.80M derived: sum of 4 quarters · filed 2013-02-08 | |
| 2010-12-31 | $8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $10.37M derived: sum of 2 quarters · filed 2013-02-08 | $12.62M derived: sum of 3 quarters · filed 2013-02-08 | $15.75M 10-K · filed 2013-02-08 | |
| 2010-09-30 | $2.36M 10-Q · filed 2011-11-03 | $4.61M derived: sum of 2 quarters · filed 2011-11-03 | $7.74M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | $2.25M 10-Q · filed 2011-08-04 | $5.38M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $21.06M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |